Amneal Pharmaceuticals, Inc.
AMRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $3 | $3 | $3 | $2 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $3 | $3 | $3 | $3 |
| Enterprise Value | $6 | $5 | $5 | $5 |
| Revenue | $1 | $1 | $1 | $1 |
| % Growth | 8.3% | 4.2% | -4.8% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 34.9% | 39.5% | 36.8% | 36% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 14.2% | 24.4% | 22.2% | 15.4% |
| Net Income | $0 | $0 | $0 | -$0 |
| % Margin | 0.3% | 3.1% | 1.8% | -4.3% |
| EPS Diluted | 0.008 | 0.07 | 0.038 | -0.1 |
| % Growth | -89.2% | 84.8% | 137.6% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | -$0 | $0 |